A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

被引：65
|
作者：
Cha, Yoon Jin [1 ]
Cho, Byoung Chul [2 ]
Kim, Hye Ryun [2 ]
Lee, Hye-Jeong [3 ]
Shim, Hyo Sup [1 ]
机构：
[1] Yonsei Univ, Severance Hosp, Dept Pathol, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Yonsei Canc Ctr, Dept Oncol, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Severance Hosp, Dept Radiol, Coll Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 05期
关键词：
Lung adenocarcinoma; Anaplastic lymphoma kinase; Crizotinib; Resistance; Small cell lung carcinoma;
D O I：
10.1016/j.jtho.2015.12.097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：E55 / E58
页数：7
相关论文
共 50 条
  • [1] Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies
    Kobayashi, Yoshihisa
    Sakao, Yukinori
    Ito, Simon
    Park, Jangchul
    Kuroda, Hiroaki
    Sakakura, Noriaki
    Usami, Noriyasu
    Mitsudomi, Tetsuya
    Yatabe, Yasushi
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : E75 - E78
  • [2] TRANSFORMATION TO SARCOMATOID CARCINOMA IN ALK-REARRANGED ADENOCARCINOMA WHICH DEVELOPED ACQUIRED RESISTANCE TO CRIZOTINIB AND RECEIVED SUBSEQUENT CHEMOTHERAPIES
    Kobayashi, Yoshihisa
    Sakao, Yukinori
    Ito, Simon
    Park, Jangchul
    Mizuno, Tetsuya
    Kuroda, Hiroaki
    Sakakura, Noriaki
    Usami, Noriyasu
    Mitsudomi, Tetsuya
    Yatabe, Yasushi
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S958 - S958
  • [3] Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer
    Qi, Xiaolong
    Ma, Wang
    Li, Sen
    Zhou, Caicun
    LUNG CANCER, 2014, 85 (02) : 335 - 336
  • [4] Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor
    Park, Sehhoon
    Han, Joungho
    Sun, Jong-Mu
    LUNG CANCER, 2019, 127 : 66 - 68
  • [5] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
    Cappuzzo, Federico
    Moro-Sibilot, Denis
    Gautschi, Oliver
    Boleti, Ekaterini
    Felip, Enriqueta
    Groen, Harry J. M.
    Germonpre, Paul
    Meldgaard, Peter
    Arriola, Edurne
    Steele, Nicola
    Fox, Jesme
    Schnell, Patrick
    Engelsberg, Arne
    Wolf, Juergen
    LUNG CANCER, 2015, 87 (02) : 89 - 95
  • [6] Small-cell transformation o f ALK-rearranged non-small-cell adenocarcinoma of the lung
    Balla, Agnes
    Khan, Farrah
    Hampel, Kenneth J.
    Aisner, Dara L.
    Sidiropoulos, Nikoletta
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2018, 4 (02):
  • [7] Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
    Katayama, Ryohei
    Shaw, Alice T.
    Khan, Tahsin M.
    Mino-Kenudson, Mari
    Solomon, Benjamin J.
    Halmos, Balazs
    Jessop, Nicholas A.
    Wain, John C.
    Yeo, Alan Tien
    Benes, Cyril
    Drew, Lisa
    Saeh, Jamal Carlos
    Crosby, Katherine
    Sequist, Lecia V.
    Iafrate, A. John
    Engelman, Jeffrey A.
    SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)
  • [8] Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
    Katayama, Ryohei
    Shaw, Alice T.
    Khan, Tahsin M.
    Mino-Kenudson, Mari
    Iafrate, Anthony J.
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2012, 72
  • [9] Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma
    Mattar, Marissa S.
    Chang, Jason
    Benayed, Ryma
    Halpenny, Darragh
    Powers, Astin
    Kleiner, David E.
    Drilon, Alexander
    Kris, Mark G.
    CLINICAL LUNG CANCER, 2020, 21 (01) : E25 - E29
  • [10] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    TUMORI JOURNAL, 2016, 102 : S46 - S49
12345